Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ISIS > SEC Filings for ISIS > Form 8-K on 21-Aug-2014All Recent SEC Filings




Other Events

Item 8.01. Other Events.

On August 21, 2014, the first infant received their first dose of ISIS-SMNRx in the Isis Pharmaceuticals, Inc. ("Isis") Phase 3 study, ENDEAR, which is evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). Isis earned an $18 million milestone payment from its development partner, Biogen Idec International Holding Ltd as a result of Isis' achievement of this milestone event. The ENDEAR study, is the first Phase 3 clinical study for ISIS-SMNRx. Isis plans to initiate a second pivotal study in children with SMA later this year and additional studies are in the planning stages. Additional information regarding the ENDEAR study may be found at the following website: Any information that is included on or linked to the foregoing website is not part of this current report or any registration statement or report that incorporates this current report by reference.


This current report includes forward-looking statements regarding Isis' alliance with Biogen Idec International Holding Ltd and the development of ISIS-SMNRx for the treatment of spinal muscular atrophy. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from Isis.

  Add ISIS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ISIS - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.